Torasemide
- Generic Name
- Torasemide
- Brand Names
- Demadex, Soaanz
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20N4O3S
- CAS Number
- 56211-40-6
- Unique Ingredient Identifier
- W31X2H97FB
- Background
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
- Indication
Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.
As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.
- Associated Conditions
- Edema, Hypertension
Open Label Study for the Functional Characterization of Drug Metabolism and Transport
- Conditions
- Genotype-related Drug Metabolism
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Matthias Schwab
- Target Recruit Count
- 144
- Registration Number
- NCT01788254
- Locations
- 🇩🇪
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
🇩🇪Abteilung Klinische Pharmakologie, Tübingen, Germany
A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)
- Conditions
- Heart FailureRenal Impairment
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01558674
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01276288
- Locations
- 🇩🇪
1245.42.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Bioavailability Study of Torsemide Tablets Under Fasting Conditions
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00653549
Bioavailability Study of Torsemide Tablets Under Fed Conditions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2008-04-11
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00654043
Bioequivalency Study of Torsemide Tablets Under Fed Conditions
- Conditions
- Edema
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT00602615
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States
Bioequivalency Study of Torsemide Tablets Under Fasting Conditions
- Conditions
- Edema
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 28
- Registration Number
- NCT00602303
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States
Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
- Conditions
- Congestive Heart Failure
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 142
- Registration Number
- NCT00409942
- Locations
- 🇪🇸
Central Hospital, Oviedo, Asturias, Spain
🇪🇸Centelles - Primar Care Centre, Centellas, Barcelona, Spain
🇪🇸San Jorge Hospital, Huesca, Spain
Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.
- Conditions
- Hypertension
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 388
- Registration Number
- NCT00334386
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.